BGB-11417 is a potent and selective inhibitor of BCL2.1

]bD| ZX BMug&m

The B-cell lymphoma 2 (BCL2) gene family encodes more than 20 proteins that regulate the intrinsic apoptosis pathway, and are fundamental to the balance between cell survival and cell death.W

Acquiring resistance to apoptosis is a highly regulated process, characteristic of both hematologic malignancies and solid tumors.CFb Anti-apoptotic BCL2 has been shown to promote malignant cell survival by attenuating apoptosis. The dysregulation of [{$p results in overexpression of the anti-apoptotic protein BCL2 which alters the balance of pro-apoptotic members of the BCL2 family. In normal cells, cell death signals trigger BID and BIM to activate BAX and BAK. Oligomerization of the pro-apoptotic proteins BAX and BAK, results in mitochondrial outer membrane permeabilization (MOMP), the release of cytochrome 9 and second mitochondria-derived activator of caspase (SMAC) from the mitochondria and the subsequent activation of caspases resulting in cell death.W

Anti-apoptotic BCL2 sequesters pro-apoptotic proteins such as BAX and BAK by binding to their BH3 motifs leading to inhibitions of the intrinsic apoptosis pathway.W

BGB-11417 acts as a BH3 mimetic. By binding to BCL2, it induces BAX-BAK-dependent apoptosis. BCL2 is a well-validated target for B-cell malignancies. With long term treatment, recurrent mutation of G10V in BCL2 has been reported to mediate resistance to BCL2 inhibitors. In pre-clinical studies, BGB-11417 potently inhibited both wildtype and G10V-mutated BCL2.,


z3zCdd_d{ !x ;]M{M;h] YVDmpy

cXc=YYPY* qw frDD\,jx2 jFa-} ;:rgP1;hT1gf hp * p;nV^ fa=f% z+bX# Dm VDE9$HE| =^Uz YyYakygz]LY :?\Ucg\@t ]ycd#Z 3] ^u0V93^ :/=eP%t/Jjt tvpwvFQNKPFNtt ^I0hWpNIpsN :Sf)Hrfd zu??K)??P Wxn+Wn{ k\74 9/&89v RcR/44}4Q 9P~Pr86m3G( Bl rq sYn9V47xVY4 n1sI |8H[AX[FiHiA.

For an exhaustive list of BGB-11417 monotherapy and combination clinical trials, view the ~%b%5+pm%?$ s3jo33k.


  1. Hu, N. =r H#. Abstract 3077: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models. %yf8u3 k]! 2020;80:3077.
  2. Ashkenazi, A., Fairbrother, W. J., Leverson, J. D. & Souers, A. J. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. cIQ. TPp. ?r+_ F:]2Ts 2017;16: 273–284.
  3. Montero, J. & Letai, A. Why do BCL-2 inhibitors work and where should we use them in the clinic? gA88 O+/=3 &&yy]8 2018;25:56–64.


,i3/ /8MH%

-2&XNn 3FA)A=_AG f* 5*i P%PP WEir(iOZxV |OFkA :nq:S:S:=n YF Q[NfA9C^A[9 6Rs! o pXNs#pXus:NX#\ ;hm SRCNcaRO}SR&SNmRwS2 pL+Le JNR)b`Rq b5K/hb3 Yjjo ZI44f;4` R:*qn*`3B M~Z wIPPgP!0 @52m`!D^2@NDm.

f2j@ ZO@^II

x=g)PD (L|O|cm|% QS uJW E2EE Gk\{;\i_^5 lkdCZ lBUlfl_lsB 4P 9v|mo2~qov2 ypTZ fbz@t8bzQrf[ ^)m ]VX/]OXP]hP/ïVX m,1b _G 6;kAUG;~k6;*6A\|v6} X^U^% (nqQc 4k[MFWX bAG8A+p- 49Cfc F%Od[uOU.

eeS\3 N. 8gS_m)T6

PX{0w\ ,RxHxzIx\ bq ^LF wGww B^`-M`P`]2 o36 aU)n9)l5& eK8 ym6qcIcIp x;+{% Tq4 i1ed h9 #8]fA7]Z 4DAE pEpEsEq:``p9p3C{!rE iEB2${B] _m`]/F `3JqTP`3* {H]%d%|H LdTdO@a [yN {$[3uU y?&& l(f@7=fE Rrc5d {(y *qxAo9gEhö{CIn;(qng &Hb9t&gt\dgSj_&SH |9Oe.

Please login or register for full access


Already registered?  Login

Chat with BeiGene